ECA Academy reported three Data Integrity and IT Compliance Group developments. The update appeared on May 29, 2026. It covered work completed from January through April 2026. Activities included Annex 22 input, contract guidance, and AI planning. These efforts matter because uncontrolled digital systems can weaken GMP evidence.
Why Is ECA Expanding Data Integrity Work?
ECA’s Data Integrity and IT Compliance Group reported three developments from January through April 2026. The group joined ECA Board members in an EMA meeting supporting an Annex 22 expert workshop. It also began an ECA guideline on contracts and finalized an AI conference. These activities address governance gaps affecting computerized systems, responsibilities, traceability, and GMP records across regulated operations.
AI Governance Creates Compliance Risks and Opportunities
Poor AI governance, weak supplier contracts, and unclear computerized-system ownership can create data integrity failures, inspection findings, and unreliable quality decisions. Annex 22, EMA engagement, and ECA contract guidance may offer a stronger framework. Clear responsibilities could improve validation, audit trails, change control, and lifecycle oversight. However, companies must translate emerging expectations into SOPs and risk assessments before automated tools directly influence GMP records, laboratory results, or batch release decisions.
Why Annex 22, AI, and Data Integrity Matter to Pharma Professionals
Annex 22, AI governance, and data integrity increasingly shape daily pharmaceutical responsibilities. QA professionals, computerized-system specialists, and regulatory teams must understand emerging expectations. Their work determines whether automation remains validated, transparent, contractually controlled, and defensible during inspections across regulated operations.
Quality Assurance Professionals
Quality assurance professionals must ensure AI-supported processes remain governed within the pharmaceutical quality system. They should define oversight, approve risk controls, and prevent automated decisions from bypassing documented GMP responsibilities.
- Define ownership for every automated quality decision.
- Review AI risks through change control.
Computerized-System Specialists
Computerized-system specialists must validate intended use, access controls, audit trails, and data flows. Emerging Annex 22 expectations increase pressure to explain AI performance, limitations, changes, and continued control during operation.
- Validate AI systems against intended use.
- Review audit trails and access permissions.
Regulatory and Supplier-Quality Teams
Regulatory and supplier-quality teams must translate contracts into measurable responsibilities for data, validation, security, and monitoring. Weak agreements can leave critical AI controls unassigned during inspections or serious vendor failures.
- Define supplier responsibilities within quality agreements.
- Monitor vendor controls throughout system lifecycles.
What Could Stronger AI Governance Achieve?
ECA’s three initiatives show that AI compliance is moving from discussion toward governance in 2026. Annex 22 engagement, contract guidance, and the October 7–8 conference may strengthen industry alignment. Companies should now map AI uses, assign ownership, validate controls, and update SOPs before regulatory expectations become harder to meet.
Want to strengthen digital data governance? Explore Pharmuni’s GMP Master Data Management course to understand regulated data classifications, change control, traceability, and integrity assessments. Build practical knowledge for managing master data, computerized systems, and quality-relevant records across modern pharmaceutical operations.